Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV

Autor(es)

Sadraeian, Mohammad ^[1] ; da Cruz, Edgar Ferreira ^[2] ; Boyle, Ross W. ^[3] ; Bahou, Calise ^[4] ; Chudasama, Vijay ^[4] ; Ramos Janini, Luiz Mario ^[2] ; Diaz, Ricardo Sobhie ^[2] ; Guimaraes, Francisco E. G. ^[1]

Afiliação do(s) autor(es)

^[1] Sao Carlos Inst Phys, BR-13560970 Sao Carlos, SP - Brazil

^[2] Univ Fed Sao Paulo, Lab Retrovirol, Sao Paulo - Brazil

^[3] Univ Hull, Dept Chem, Kingston Upon Hull HU6 7RX, N Humberside - England

^[4] UCL, Dept Chem, London WC1H 0AJ - England

• Tipo de documento: Artigo Científico
• Fonte: ACS OMEGA; v. 6, n. 25, p. 16524-16534, JUN 29 2021.
• Citações Web of Science: 0

Resumo

HIV-infected cells persist for decades in patients administered with antiretroviral therapy (ART). Meanwhile, an alarming surge in drug-resistant HIV viruses has been occurring. Addressing these issues, we propose the application of photo-immunotherapy (PIT) against not only HIV Env-expressing cells but also HIV. Previously, we showed that a human anti-gp41 antibody (7B2) conjugated to cationic or anionic photosensitizers (PSs) could specifically target and kill the HIV Env-expressing cells. Here, our photolysis studies revealed that the binding of photoimmunoconjugates (PICs) on the membrane of HIV Env-expressing cells is sufficient to induce necrotic cell death due to physical damage to the membrane by singlet oxygen, which is independent of the type of PSs. This finding persuaded us to study the virus photoinactivation of PICs using two HIV-1 strains, X4 HIV-1 NL4-3 and JR-CSF virus. We observed that the PICs could destroy the viral strains, probably via physical damage on the HIV envelope. In conclusion, we report the application of PIT as a possible dual-tool for HIV immunotherapy and ART by killing HIV-expressing cells and cell-free HIV, respectively. (AU)

• Processo FAPESP: 13/11323-5 - Uso de vacina de células dendríticas em associação com estratégias para eliminação de reservatórios virais almejando a cura esterilizante da infecção pelo HIV-1 em pessoas cronicamente infectadas em uso de tratamento antirretroviral
• Beneficiário: Ricardo Sobhie Diaz
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/07276-1 - CEPOF - Centro de Pesquisa em Óptica e Fotônica
• Beneficiário: Vanderlei Salvador Bagnato
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs